Funding Update: Innovative Medicines Initiative (IMI) Launches Final IMI2 Calls for Proposals
The Innovative Medicines Initiative (IMI), part of the European Research and Innovation Programme Horizon 2020 has launched its last calls for proposals under the IMI2 programme.
The IMI will contribute a total of EUR 59 million to a broad range of projects which will support tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, the return of clinical trial data to participants, and patient adherence.
The IMI encourages the participation in the projects of organisations such as universities, small and medium-sized enterprises, and patient groups.
In addition to the EUR 59 million funding provided via Horizon 2020 EFPIA companies and IMI Associated Partners will contribute EUR 47 million, mostly as ‘in kind’ contributions (e.g. staff time, access to equipment, etc).
Please note that the Calls are also available on the EU Funding Portal.